Description
Springer Controlled Clinical Trials in Neurological Disease 1st Editon 2011 Softbound by Roger J. Porter, Bruce S. Schoenberg
The evaluation of the efficacy and safety of a clinical tool, be it a diagnostic technique, a preventive methodology, or a therapeutic intervention, is an im portant responsibility of physicians. The history of medicine is characterized by the authoritarianisms of teachers and of organizations giving way to the clinical experience of physicians; authoritarian dictum was replaced by case report and then by case series. As physicians learned to substitute the analysis of data for the inconsistencies of dictums and anecdotes, the problems of the case series as an investigative tool became more evident: patient selection criteria, measurements of outcome, significance of results, and extrapolation of conclusions to the community of patients. In response to these issues, the methodology of the controlled clinical trial has evolved and with it the instru ments of study design and of biostatistics as aids to study design and data analysis. The medical - surgical armamentarium has evolved from being dependent solely upon the observations and conclusions of a skilled clinician to being constructed upon the systematic collection and evaluation of data by a team of skilled clinicians and their statistical colleagues: this is the controlled clinical trial. During the past two decades, the evaluation of clinical approaches to pre vention and therapy has become particularly important to clinicians concerned with nervous system dysfunction. There has been and continues to be an explosion of information from the basic neurosciences and from the applica tion of biotechnology to the nervous system. I. Design of Controlled Clinical Trials.- 1. Clinical considerations.- 2. Initial statistical considerations.- 3. Statistical and epidemiological considerations.- II. Implementation and Interpretations of Controlled Clinical Trials (Example: Epilepsy).- 4. Perspective of the patient.- 5. Perspective of the participating investigator.- 6. Perspective of the clinical center.- 7. Perspective of the coordinating center.- 8. Perspective of the food and drug administration.- 9. Perspective of the pharmaceutical industry.- 10. Perspective of the insurance industry.- III. Applications of Controlled Clinical Trials to Diseases of the Nervous System.- 11. Cerebrovascular disease.- 12. Epilepsy.- 13. Movement disorders.- 14. Head and spinal cord injury.- 15. Headache.- 16. Peripheral neuropathy.- 17. Guillain-Barré: Plasmapheresis.- 18. Motor neuron disease.- 19. Myasthenia gravis.- 20. Muscular dystrophy.- 21. Multiple sclerosis.- 22. Brain tumors.- 23. Alzheimer’s disease.- 24. Viral diseases: Herpes simplex encephalitis.- 25. Parasitic diseases.